Abstract:BackgroundRecently, the discovery of the elansolids, a group of macrolides, was reported. The molecules show activity against methicillin-resistant Staphylococcus aureus as well as other gram-positive organisms. This fact renders those substances a promising starting point for future chemical development. The active atropisomers A1/A2 are formed by macrolactonization of the biosynthesis product A3 but are prone to ring opening and subsequent formation of several unwanted side products. Recently it could be shown that addition of different nucleophiles to culture extracts of Chitinophaga sancti enable the formation of new stable elansolid derivatives. Furthermore, addition of such a nucleophile directly into the culture led exclusively to formation of a single active elansolid derivative. Due to low product yields, methods for production of gram amounts of these molecules have to be established to enable further development of this promising compound class.ResultsProduction of elansolid A2 by C. sancti was enabled using a synthetic medium with sucrose as carbon source to a final concentration of 18.9 mg L−1. A fed-batch fermentation was ensued that resulted in an elansolid A2 concentration of 55.3 mg L−1. When using glucose as carbon source in a fed-batch fermentation only 34.4 mg L−1 elansolid A2 but 223.1 mg L−1 elansolid C1 were produced. This finding was not unexpected since elansolids A1/A2 and A3 have been reported to easily react with nucleophiles like anthranilic acid, a precursor of tryptophan biosynthesis. Due to the fact that nucleophiles can be incorporated in vivo, a fed-batch cultivation under identical conditions, with addition of anthranilic acid was carried out and lead to almost exclusive formation of elansolid C1 (257.5 mg L−1).ConclusionReproducible elansolid A2 and C1 production is feasible in different synthetic media at relatively high concentrations that will allow further investigation and semi-synthetic optimization. The feeding of anthranilic acid enables the exclusive production of the stable elansolid derivative C1, which reduces product loss by unspecific reactions and eases downstream processing. This derivative shows activity in the same range as the elansolids A1/A2. Hence, the method can possibly serve as a model-process for incorporation of other nucleophiles and biotechnological production of specifically designed molecules.

Asymmetric Total Synthesis of Antibiotic Elansolid A

Asymmetric Total Synthesis Towards the Simplified Analogs of Antibiotic Elansolid A

Total Synthesis of (+)-Jatrophalactam

Stereoselective Total Synthesis and Structural Elucidation of (-)-indoxamycins A-F.

Total Synthesis and Structural Revision of Antibiotic CJ‐16,264

Asymmetric Total Synthesis and Absolute Configuration Reassignment of Indole Alkaloid (+)-Alsmaphorazine D

Total Synthesis of the Potent and Broad-Spectrum Antibiotics Amycolamicin and Kibdelomycin

Asymmetric Total Synthesis of Ieodomycin B

Asymmetric Total Synthesis of (−)-Awajanomycin

Synthetic Approaches For Building Tricyclic Cage-Like Motifs Found In Indoxamycins

Total Synthesis of Kibdelomycin

Total Synthesis of Three Families of Natural Antibiotics: Anthrabenzoxocinones, Fasamycins/Naphthacemycins, and Benastatins

Optimization of the biotechnological production of a novel class of anti-MRSA antibiotics from Chitinophaga sancti

Total Synthesis of (−)-Platensimycin, a Novel Antibacterial Agent

Asymmetric Total Synthesis of Nannocystin A

Asymmetric total synthesis of polycyclic xanthenes and discovery of a WalK activator active against MRSA

Asymmetric total syntheses of ansamacrolactams (+)-Q-1047H-A-A and (+)-Q-1047H-R-A.

Asymmetric Total Synthesis of (−)-Cebulactam A1

Asymmetric Syntheses of Four Stereoisomers of 13-Hydroxy-14-methylhexadecanoic Acid As Potential Antibacterial Agents

Asymmetric Total Synthesis of Cytotrienin A: Late‐Stage Installation of C11 Side Chain Onto the Macrolactam Scaffold

Calixanthomycin A: Asymmetric Total Synthesis and Structural Determination